Aptose Biosciences APTO
$ 0.19
2.66%
Quarterly report 2024-Q2
added 08-08-2024
Aptose Biosciences Financial Ratios 2011-2024 | APTO
Annual Financial Ratios Aptose Biosciences
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.9 | -1.0 | -1.4 | -6.1 | -13.2 | -2.4 | -5.8 | - | -3.3 | -3.0 | -1.6 | -2.1 | -1.8 |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.6 | -1.7 | -0.7 | -0.7 | -0.5 | -0.9 | -0.5 | - | - | - | - | - | - |
EV (Enterprise Value) |
17.4 M | -13.8 M | 58.3 M | 227 M | 273 M | 55.9 M | 58.7 M | 1.32 M | 36.7 M | 31.7 M | 10.6 M | 11.9 M | 10.4 M |
EBITDA per Share |
0.01 | 0.02 | 0.00168 | -0.674 | -0.533 | -0.868 | -0.523 | - | -0.952 | -1.68 | -1.52 | -2.62 | -4.6 |
EV/EBITDA |
388.4 | -4.0 | -10.0 | -1.8 | -4.9 | - | -2.4 | -1.4 | -1.5 | -2.2 | -1.6 | ||
PEG |
-0.0 | -0.0 | - | 0.21 | -0.33 | 0.04 | -0.11 | - | -0.06 | 0.12 | -0.04 | -0.05 | 0.01 |
P/B |
-3.7 | 0.3 | 1.2 | 2.8 | 3.7 | 4.9 | 6.6 | - | 2.6 | 1.1 | -11.7 | -4.7 | 10.6 |
P/CF |
-0.2 | -0.3 | -2.1 | -9.9 | -16.0 | -2.9 | -6.6 | - | -3.7 | -3.7 | -1.8 | -4.0 | -1.5 |
ROE % |
412.10 | -26.50 | -88.04 | -46.45 | -27.98 | -205.01 | -114.30 | - | -77.41 | -37.11 | 712.55 | 227.51 | -596.21 |
ROA % |
-92.04 | -19.60 | -79.19 | -43.75 | -26.15 | -171.12 | -97.44 | - | -68.83 | -34.15 | -537.68 | -690.72 | -251.40 |
ROCE % |
- | - | - | -46.69 | -28.29 | -206.71 | -115.92 | -33.65 | -85.21 | -33.17 | 715.62 | 226.82 | -589.47 |
Current Ratio |
0.8 | 3.8 | 10.0 | 18.4 | 17.8 | 5.9 | 6.7 | 8.8 | 8.8 | 16.0 | 0.6 | 0.2 | 1.1 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Aptose Biosciences
2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.43 | -0.73 | - | -1.76 | -2.27 | -2.22 | - | -1.59 | -1.72 | -0.12 | -0.27 | -0.13 | -0.15 | -0.18 | -0.17 | -0.15 | -0.21 | -0.15 | -0.13 | -0.12 | -0.13 | -0.14 | -0.17 | -0.16 | -0.3 | -0.23 | -0.12 | -0.11 | -0.11 | -0.19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-6997.64 | -7433.40 | -302.31 | -323.20 | -196.87 | -113.42 | -57.51 | -90.28 | -82.17 | -76.85 | -74.10 | -53.70 | -52.07 | -51.59 | -46.45 | -42.29 | -38.43 | -31.81 | -27.98 | -64.23 | -96.23 | -162.48 | -205.01 | -192.60 | -180.20 | -131.00 | -124.96 | -92.90 | -66.03 | -42.35 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-251.24 | -238.17 | -142.77 | -159.91 | -122.22 | -84.86 | -48.76 | -78.24 | -56.95 | -69.63 | -67.90 | -50.08 | -48.91 | -48.71 | -43.75 | -39.77 | -36.09 | -29.80 | -26.15 | -55.59 | -81.57 | -136.21 | -171.12 | -161.33 | -128.55 | -67.72 | -27.33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
0.8 | 1.0 | 0.8 | 1.6 | 2.1 | 3.0 | 3.8 | 5.6 | - | 9.9 | 10.0 | 11.4 | 13.2 | 19.9 | 17.2 | 17.2 | 17.2 | 17.2 | 15.3 | 15.3 | 15.3 | 15.3 | 6.0 | 6.0 | 6.0 | 6.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency